🔎 Trials Near Me

Home › Lung Cancer › Washington

Lung Cancer clinical trials in Washington

43 studies for Lung Cancer are looking for participants at sites in Washington.

Cities in Washington

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

  • University of Washington - Fred Hutchinson Cancer Center, Seattle
  • Compass Oncology, Vancouver
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT06765109

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

  • Swedish Cancer Institute-Edmonds, Edmonds
  • Swedish Cancer Institute-Issaquah, Issaquah
  • Swedish Medical Center-First Hill, Seattle
RecruitingPhase 3
Ages 70 and older · All sexes · Updated Sep 30, 2026 · NCT06096844

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

  • Kadlec Clinic Hematology and Oncology, Kennewick
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT04181060

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

  • Swedish Cancer Institute-Edmonds, Edmonds
  • Swedish Cancer Institute-Issaquah, Issaquah
  • Swedish Medical Center-First Hill, Seattle
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06498635

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  • American Oncology Network Vista Oncology Division-West office, Olympia
  • American Oncology Network Vista Oncology Division-East office, Olympia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06758401

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

  • Research Site, Edmonds
  • Research Site, Seattle
RecruitingPhase 2
Ages 18 to 95 · All sexes · Updated Sep 23, 2026 · NCT05061550

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

  • Swedish Medical Center, Seattle
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06618287

Tailored Patient Navigation to Improve the Uptake of Lung Cancer Screening in Tribal Communities in Western Washington State, SACRED LUNGS Trial

  • Muckleshoot Tribal Clinic, Auburn
  • South Puget Intertribal Planning Agency (SPIPA), Shelton
RecruitingHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT07176000

A Restorative Justice-Based Lung Cancer Screening Decision-Making Support Intervention Tailored for Black Individuals to Increase Lung Cancer Screening Among Black Community Members, RESTORE Trial

  • Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingHealthy volunteers welcome
Ages 50 to 77 · All sexes · Updated Sep 17, 2026 · NCT07490860

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

  • Fred Hutchinson Cancer Research Center, Seattle
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT05786924

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • University of Washington, Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 15, 2026 · NCT04585750

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

  • Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06625775

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  • Swedish Cancer Institute - Edmonds, Edmonds
  • Kadlec Clinic Hematology and Oncology, Kennewick
  • Swedish Medical Center, Seattle
  • and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT06119581

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

  • Avenzo Therapeutics Recruiting Site, Seattle
RecruitingPhase 1/2
Ages 18 to 75 · All sexes · Updated Sep 4, 2026 · NCT07038343

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

  • Fred Hutchinson Cancer Center, Seattle
  • Northwest Medical Specialties, Tacoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06343402

The Vanguard Study: Testing a New Way to Screen for Cancer

  • Madigan Army Medical Center, Tacoma
RecruitingHealthy volunteers welcome
Ages 45 to 75 · All sexes · Updated Sep 2, 2026 · NCT06995898

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Providence Regional Cancer System-Aberdeen, Aberdeen
  • PeaceHealth Saint Joseph Medical Center, Bellingham
  • Providence Regional Cancer System-Centralia, Centralia
  • and 19 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Sep 2, 2026 · NCT05334069

SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer

  • Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 31, 2026 · NCT07322341

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

  • Virginia Mason Medical Center, Seattle
  • Legacy Cancer Institute Medical Oncology and Day Treatment, Vancouver
  • Legacy Salmon Creek Hospital, Vancouver
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT05624996

Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer

  • Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 14, 2026 · NCT06518057

PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer

  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Recruiting
Ages 18 and older · All sexes · Updated Aug 6, 2026 · NCT04151940

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

  • Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT07444814

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

  • Xencor Investigative Site, Seattle
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 3, 2026 · NCT05433142

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

  • Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT05098210

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

  • Fred Hutch Cancer Center, Seattle
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 15, 2026 · NCT05652686

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

  • Fred Hutchinson Cancer Research Center, Seattle
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 30, 2026 · NCT06162221

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

  • Seattle Cancer Care Alliance, Seattle
RecruitingPhase 2
Ages 18 to 70 · All sexes · Updated Jun 26, 2026 · NCT04614103

SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer

  • Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 17, 2026 · NCT05570825

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

  • Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 12, 2026 · NCT06051695

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

  • FHCC Overlake, Bellevue
  • FHCC at EvergreenHealth, Kirkland
  • Valley Medical Center, Renton
  • and 4 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 3, 2026 · NCT05642572

MYLUNG Consortium Part 3: Observational Study

  • Northwest Cancer Specialists, P.C., Vancouver
RecruitingObservational study
Ages 18 and older · All sexes · Updated May 18, 2026 · NCT05885698

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

  • Virginia Mason Medical Center, Seattle
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated May 15, 2026 · NCT05379985

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

  • Swedish Cancer Institute-Edmonds, Edmonds
  • Swedish Cancer Institute-Issaquah, Issaquah
  • Swedish Medical Center-First Hill, Seattle
RecruitingPhase 2
18 Minutes · All sexes · Updated May 5, 2026 · NCT06031688

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

  • Virginia Mason Medical Center, Seattle
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 22, 2026 · NCT07020221

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

  • Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT06778863

From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.